Boston Scientific Corporation ($BSX) Stock Forecast: Up 5.2% Today

What is Boston Scientific Corporation?

Boston Scientific Corporation ($BSX) is a leading medical technology company known for its innovative medical solutions that enhance patient care. The company recently posted robust financial results, surpassing Q3 projections and garnering favorable ratings from analysts.

Why is Boston Scientific Corporation going up?

BSX stock is up 5.2% on Dec 17, 2025 15:40

• A notable decrease in Thurston Springer Miller Herd & Titak Inc.'s stake might have sparked some initial investor concerns. However, the positive Q3 outcomes and analyst ratings likely alleviated apprehensions, bolstering confidence in the company's future outlook.
• Insider sales totaling $14.23 million could be viewed as stock-profit realization by company insiders, showing their faith in the current stock prices and growth potential.
• Today's bullish trend in BSX's stock price seems to stem from strong financial performance, positive analyst evaluations, and investor trust in the company's strategic vision.

BSX Price Chart

BSX Technical Analysis

BSX News

Boston Scientific Corporation $BSX Position Trimmed by Thurston Springer Miller Herd & Titak Inc.

Thurston Springer Miller Herd & Titak Inc. significantly reduced its stake in Boston Scientific Corporation ($BSX) by 93.2% in the third quarter of 2025. This comes as company insiders sold a total of 143,095 shares worth $14.23 million, despite Boston Scientific beating its Q3 estimates with $0.75 EPS and $5.07B revenue, and receiving mostly "Buy" ratings from analysts with an average target price of $125.40.

https://www.marketbeat.com/instant-alerts/filing-boston-scientific-corporation-bsx-position-trimmed-by-thurston-springer-miller-herd-titak-inc-2025-12-17/

ST Germain D J Co. Inc. Buys 14,058 Shares of Zimmer Biomet Holdings, Inc. $ZBH

https://www.marketbeat.com/instant-alerts/filing-st-germain-d-j-co-inc-buys-14058-shares-of-zimmer-biomet-holdings-inc-zbh-2025-12-17/

Uterine Fibroid Treatment Market Forecast to 2032 Reveals Key

Coherent Market Insights has released a comprehensive report on the Uterine Fibroid Treatment Market, forecasting trends and growth opportunities from 2025-2032. The report analyzes key market players like Hologic Inc., AbbVie Inc., and Medtronic plc, along with market segmentation, regional analysis, and strategic growth factors. It serves as an essential tool for stakeholders interested in the evolving dynamics of this market.

https://www.openpr.com/news/4319227/uterine-fibroid-treatment-market-forecast-to-2032-reveals-key

BioMEMS Market Hits New High | Major Giants Agilent

The global BioMEMS Market is projected to grow at an 8% CAGR from 2025 to 2032, reaching $2.7 billion, driven by rising lab-on-chip adoption, diagnostics miniaturization, and point-of-care testing. Key players include Abbott, Medtronic, and Agilent Technologies. The market faces challenges in biocompatibility and manufacturing complexity but sees opportunities in implantable monitoring and wearable healthcare devices.

https://www.openpr.com/news/4318559/biomems-market-hits-new-high-major-giants-agilent

Regency Centers Elects Mark J. Parrell to Board of Directors

Regency Centers Corporation announced the election of Mark J. Parrell to its Board of Directors, effective January 1, 2026, expanding the board to twelve directors. Mr. Parrell, currently the President, CEO, and a board member of Equity Residential, brings extensive real estate and financial leadership experience. His expertise is expected to be invaluable as Regency Centers continues to execute its strategy and create long-term shareholder value.

https://www.globenewswire.com/news-release/2025/12/16/3206209/37116/en/Regency-Centers-Elects-Mark-J-Parrell-to-Board-of-Directors.html

Trending Today

DXC Technology Company ($DXC) Stock Forecast: Up 5.5% Today

CleanSpark Inc ($CLSK) Stock Forecast: Down 5.2% Today

Plug Power Inc. ($PLUG) Stock Forecast: Down 6.2% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 5.3% Today

Blink Charging Co. ($BLNK) Stock Forecast: Up 6.8% Today

Stitch Fix Inc. ($SFIX) Stock Forecast: Up 5.1% Today

Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Up 7.6% Today

Sonos Inc. ($SONO) Stock Forecast: Down 6.8% Today

Under Armour Inc. Class A ($UAA) Stock Forecast: Up 5.9% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Down 6.7% Today

Boston Scientific Corporation Price History

24.06.2025 - BSX Stock was down 1.9%

• BSX reported strong Q2 earnings, exceeding estimates and raising its full-year outlook.
• Despite the positive earnings, the stock saw a bearish movement, possibly due to profit-taking by investors who had already factored in the positive news.
• The market's negative reaction may stem from concerns about BSX's ability to maintain its growth momentum in the future, leading some investors to sell off their positions.
• Broader market conditions or sector-specific factors could have influenced the bearish movement in BSX, despite the favorable earnings report.

17.11.2025 - BSX Stock was up 5.2%

• A notable decrease in Thurston Springer Miller Herd & Titak Inc.'s stake might have sparked some initial investor concerns. However, the positive Q3 outcomes and analyst ratings likely alleviated apprehensions, bolstering confidence in the company's future outlook.
• Insider sales totaling $14.23 million could be viewed as stock-profit realization by company insiders, showing their faith in the current stock prices and growth potential.
• Today's bullish trend in BSX's stock price seems to stem from strong financial performance, positive analyst evaluations, and investor trust in the company's strategic vision.

02.06.2025 - BSX Stock was down 2.5%

• BSX, having outpaced market performance recently, saw a downturn in its stock value.
• Comparisons to peers such as PAHC and MDT may have contributed to investor apprehension about BSX's future trajectory.
• Intensified competition from Medtronic within the MedSurg segment potentially prompted doubts regarding BSX's market stance and growth opportunities.
• Investors appeared to revisit their perspectives on BSX's value proposition, resulting in today's bearish market activity.

22.09.2025 - BSX Stock was up 5.0%

• Boston Scientific (BSX) reported strong Q3 earnings with a 19% growth in EPS, surpassing market expectations. This positive financial performance, along with raising their 2025 sales and EPS outlook, contributed to the bullish movement in the stock.
• The acquisition of Nalu Medical Inc., a maker of minimally invasive devices for chronic pain treatment, for approximately $533 million also boosted investor confidence in Boston Scientific's growth prospects.
• The company's robust cardiovascular performance, driven by innovative products like WATCHMAN FLX Pro and AGENT DCB, is expected to further enhance its earnings potential, attracting more investors to the stock.

02.08.2025 - BSX Stock was up 1.5%

• BSX had a strong bullish movement today, potentially driven by the company's consistent outperformance in the market over the past 5 years, with an average annual return of 20.59%.
• The comparison with other medical stocks may have highlighted BSX's strong performance, attracting investors looking for growth opportunities in the sector.
• Investors might be optimistic about BSX's future prospects, considering its track record of innovation and market leadership in the medical technology industry.

15.09.2025 - BSX Stock was up 4.3%

• BSX closed at $95.41 after a -1.92% shift in the latest trading session, showing a predominantly bullish trend.
• Comparisons with other value stocks like PAHC imply that BSX may offer better value, attracting more investors and positively impacting the market.
• The minor decline in the stock price could be linked to profit-taking following notable gains, yet the outlook for BSX remains optimistic.

08.11.2025 - BSX Stock was down 2.3%

• The bearish movement in BSX stock today could be linked to the negative sentiment following a recent FDA panel vote against a novel shunt implant by Johnson & Johnson for heart failure. This development might have raised concerns about the regulatory landscape for medical device firms, thus influencing the stock price of BSX.
• Although a bullish case is made for BSX focusing on revenue growth and innovation potential, the market sentiment, largely influenced by the FDA panel vote, may have overshadowed these positive aspects.
• Institutional investors showing increased interest in Zimmer Biomet Holdings, Inc. (ZBH) could have diverted attention and financial resources away from BSX, contributing to the downward trend in BSX stock.
• The emergence of Tuodao Medical in China, with a specialty in surgical robot technology, could have further impacted BSX as investors potentially shifted focus towards emerging competitors in the medical technology industry.

06.07.2025 - BSX Stock was down 2.2%

• The bearish movement in BSX today could be attributed to investors comparing the stock with GE HealthCare Technologies (GEHC) and potentially finding more value in the latter.
• The overly optimistic views of Wall Street analysts on BSX might have raised concerns among investors about the stock's actual performance, leading to a sell-off.
• Investors may have also reacted to broader market trends or specific industry news impacting medical product companies, causing a negative sentiment towards BSX in today's trading session.

23.03.2025 - BSX Stock was up 5.5%

• BSX stock demonstrated significant bullish momentum recently.
• The company disclosed Q1 earnings and revenues that exceeded expectations, signaling robust financial results.
• Market participants seem to be responding favorably to the strong performance, displaying trust in Boston Scientific's potential for growth.
• The impressive earnings and revenue figures are likely fueling heightened investor confidence and enthusiasm for the stock, contributing to its current upward trajectory.

23.03.2025 - BSX Stock was up 5.5%

• Boston Scientific Corporation (BSX) raised its annual outlook after reporting strong sales in heart devices in Q1, beating revenue and earnings estimates.
• The company's cardiovascular sales saw significant growth, particularly in cardiology products, which contributed to the overall positive performance.
• The stock price surged as investors reacted positively to the company's robust Q1 earnings and revenue results, leading to an optimistic outlook for the future.
• Boston Scientific's solid product portfolio and financial performance in Q1 2025 have instilled confidence in investors, driving the stock price higher.

10.03.2025 - BSX Stock was down 5.3%

• Analysts view BSX as a promising investment, yet the stock saw a decline, possibly linked to investors capitalizing on profits.
• Following a notable increase in BSX's share price in the previous session, today's drop suggests a shift in market sentiment.
• The stock price of BSX declined by 1.55%, potentially due to investors seizing the opportunity to secure profits following the recent upsurge.

01.09.2025 - BSX Stock was down 3.8%

• The bearish movement in Boston Scientific's stock today could be attributed to profit-taking by investors after a prolonged period of outperformance.
• The comparison between Boston Scientific and Phibro Animal Health in terms of value might have led some investors to shift their focus, causing a temporary dip in BSX stock.
• Market sentiment or broader economic factors could also have played a role in the bearish movement of Boston Scientific's stock today.